The draft lacks a clear description of the criteria for
eliminating an increasing number of non-GLP studies that indicate the possibility of toxic effects that are not mediated by interaction of BPA with the
estrogen receptor, and the Subcommittee does not agree with the exclusion of the non-GLP studies in the safety assessment.